LNCB74 — Topline data
H2 2026
We are backfilling patients to investigate particular dose levels and schedules in the expected therapeutic window, and plan to provide a trial progress update in the second half of 2026.Source filing
NXTC biotech catalysts & pipeline
NEXTCURE INC · Data as of 2026-09-08
Upcoming catalysts
AVR-001 — Topline data
early 2027
A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028.Source filing
AVR-001 — Topline data
H1 2028
A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028.Source filing